NCT06357754View on ClinicalTrials.gov

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

October 6, 2023

Primary Completion Date

October 6, 2038

Study Completion Date

October 6, 2038

Conditions
Non-Hodgkin LymphomaChronic Lymphocytic LeukaemiaMultiple Myeloma
Interventions
BIOLOGICAL

Idecabtagene vicleucel

As per product label

BIOLOGICAL

Lisocabtagene maraleucel

As per product label

Trial Locations (7)

5001

RECRUITING

Kantonsspital Aarau, Aarau

45147

RECRUITING

Universitaetsklinikum Essen (AoR), Essen

53792

WITHDRAWN

Local Institution - 0004, Madison

75235

NOT_YET_RECRUITING

Local Institution - 0008, Dallas

84112

NOT_YET_RECRUITING

Local Institution - 0010, Salt Lake City

8608556

WITHDRAWN

Local Institution - 0003, Kumamoto

442-8561

NOT_YET_RECRUITING

Local Institution - 0012, Toyokawa

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06357754 - Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | Biotech Hunter | Biotech Hunter